|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 48/00 | (2006.01) |
| A61K 35/761 | (2015.01) | ||
| A61P 27/02 | (2006.01) | ||
| C12N 15/09 | (2006.01) |
| (11) | Number of the document | 3471780 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17814223.8 |
| Date of filing the European patent application | 2017-06-16 | |
| (97) | Date of publication of the European application | 2019-04-24 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-28 |
| (46) | Date of publication of the claims translation | 2021-01-25 |
| (86) | Number | PCT/US2017/038003 |
| Date | 2017-06-16 |
| (87) | Number | WO 2017/218974 |
| Date | 2017-12-21 |
| (30) | Number | Date | Country code |
| 201662351234 P | 2016-06-16 | US |
| (72) |
BLUMENKRANZ, Mark, US
GASMI, Mehdi, US
|
| (73) |
Adverum Biotechnologies, Inc.,
1035 O`Brien Drive Suite A, Menlo Park, California 94025,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | AMD gydymas, naudojant AAV2 variantą su afliberceptu |
| TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT |
| Payment date | Validity (years) | Amount | |
| 2025-05-23 | 9 | 208.00 EUR |
| 2026-06-16 |